Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
26.44
+0.19 (0.72%)
Aug 10, 2026, 3:14 PM EDT - Market open

Dyne Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-536.96-468.18-343.89-242.16-170.96-150.03
Net Income
-519.41-446.21-317.42-235.94-168.1-149.29
Earnings Per Share
-3.33-3.47-3.37-3.95-3.23-2.93
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
898.481,111642.27123.1256.01376.57
Total Debt
219.2169.223.9927.4230.4832.64
Net Cash (Debt)
679.28941.36618.2895.69225.53343.94
Net Cash Growth
20.69%52.25%546.16%-57.57%-34.43%-0.40%
Net Cash Per Share
4.387.336.571.604.346.76

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-477.82-403.21-292.37-188.16-153.65-119.56
Capital Expenditures
-2.61-20.71-2.38-0.73-3.07-3.62
Free Cash Flow
-480.43-423.92-294.75-188.89-156.71-123.18
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.